Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Shareholders Meeting

<< Previous

Bullboard Posts

Next >>

Comment by alou180on Jun 26, 2018 10:33am

77 Views

Post# 28229481

RE:RE:Shareholders Meeting

"NOTICE IS HEREBY GIVEN that an annual general meeting (the “Meeting”) of the shareholders of iCo Therapeutics Inc. (the “Company”) will be held at the offices of Blake, Cassels & Graydon LLP, 595 Burrard Street, Suite 2600, Vancouver, British Columbia at 10:00 a.m. (Vancouver time) on June 27, 2018 for the following purposes:

to receive the consolidated financial statements of the Company for the 12 month period ended December 31, 2017 and the report of the auditors thereon;
to elect the directors of the Company for the ensuing year;
to appoint PricewaterhouseCoopers LLP as auditors of the Company until the next annual meeting of the Company and to authorize the directors of the Company to fix their remuneration;
to consider and, if deemed appropriate, to pass, with or without variation, an ordinary resolution ratifying and approving the Company’s Advance Notice Policy, as more particularly described in the accompanying Management Information Circular (the “Circular”); and
to transact such other business as may properly be brought before the Meeting."